SCHEMBL6005086

SCHEMBL6005086

CCOC(=O)Nc1ccc(C=O)cc1C

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.69
CYP1A2 P05177 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
NLRP3 Q96P20 2/20 0.50
ALDH1A1 P00352 4/20 0.49
HPGD P15428 2/20 0.49
KDM4E B2RXH2 1/20 0.49
HSD17B10 Q99714 1/20 0.49
KDR P35968 5/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
NPC1 O15118 1/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.43
EGFR P00533 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6004303 0.85 CYP1A2 (0.55) SMN1; SMN2CYP1A2CYP2C9CYP2C19NLRP3
SCHEMBL6004780 0.85 CYP1A2 (0.55) SMN1; SMN2CYP1A2CYP2C9CYP2C19NLRP3
SCHEMBL6005103 0.85 CYP1A2 (0.55) SMN1; SMN2CYP1A2CYP2C9CYP2C19NLRP3
SCHEMBL29951720 0.84 NPC1 (0.67) SMN1; SMN2ALDH1A1L3MBTL1NPC1MAPT
SCHEMBL12407193 0.82 SMN1; SMN2 (1.00) SMN1; SMN2CYP1A2CYP2C9CYP2C19NLRP3
SCHEMBL6004914 0.81 ALDH1A1 (0.54) SMN1; SMN2CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL5164739 0.81 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1HPGDKDM4EMEN1
SCHEMBL3596396 0.80 NLRP3 (0.60) SMN1; SMN2CYP1A2CYP2C9CYP2C19NLRP3
SCHEMBL7013927 0.79 ALDH1A1 (0.52) SMN1; SMN2CYP2C19ALDH1A1HPGDKDM4E
SCHEMBL6005453 0.79 CYP1A2 (0.48) SMN1; SMN2CYP1A2CYP2C9CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060167087-A1 Substituted aniline derivatives H. LUNDBECK A/S (DK) 2006-07-27 US disclosed
EP-1606247-A1 SUBSTITUTED ANILINE DERIVATIVES H. Lundbeck A/S (DK) 2005-12-21 EP disclosed
WO-2004080950-A1 SUBSTITUTED ANILINE DERIVATIVES H. LUNDBECK A/S (DK) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167087-A1 Substituted aniline derivatives CYP3A43, UGT2B7, CYP3A7 SMN1; SMN2 1408/4885CYP1A2 9/4885CYP2C9 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.